In the last trading session, 0.27 million Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $14.69 changed hands at $0.15 or 1.03% during last session, the market valuation stood at $963.52M. BCYC’s last price was a discount, traded about -95.17% off its 52-week high of $28.67. The share price had its 52-week low at $12.17, which suggests the last value was 17.15% up since then. When we look at Bicycle Therapeutics Plc ADR’s average trading volume, we note the 10-day average is 1.36 million shares, with the 3-month average coming to 596.02K.
Analysts gave the Bicycle Therapeutics Plc ADR (BCYC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.47. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BCYC as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Bicycle Therapeutics Plc ADR’s EPS for the current quarter is expected to be -0.86.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) trade information
Instantly BCYC was in green as seen at the end of in last trading. With action -7.79%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -22.79%, with the 5-day performance at -7.79% in the red. However, in the 30-day time frame, Bicycle Therapeutics Plc ADR (NASDAQ:BCYC) is -32.04% down. Looking at the short shares, we see there were 3.39 million shares sold at short interest cover period of 7.31 days.
The consensus price target for the stock as assigned by Wall Street analysts is 38, meaning bulls need an upside of 61.34% from its current market value. According to analyst projections, BCYC’s forecast low is 26 with 55 as the target high. To hit the forecast high, the stock’s price needs a -274.4% plunge from its current level, while the stock would need to soar -76.99% for it to hit the projected low.
Bicycle Therapeutics Plc ADR (BCYC) estimates and forecasts
Data shows that the Bicycle Therapeutics Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -30.93% over the past 6 months, a 39.96% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 37.17% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 5.34M. 5 analysts are of the opinion that Bicycle Therapeutics Plc ADR’s revenue for the current quarter will be 6.26M. The company’s revenue for the corresponding quarters a year ago was 5.33M and 19.53M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.18%. The estimates for the next quarter sales put growth at -67.95%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.36%. The 2024 estimates are for Bicycle Therapeutics Plc ADR earnings to increase by 40.64%.
BCYC Dividends
Bicycle Therapeutics Plc ADR is expected to release its next quarterly earnings report in January.
Bicycle Therapeutics Plc ADR (NASDAQ:BCYC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.30% of Bicycle Therapeutics Plc ADR shares while 97.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 99.10%. There are 97.81% institutions holding the Bicycle Therapeutics Plc ADR stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 22.0863% of the shares, roughly 9.4 million BCYC shares worth $190.26 million.
DEEP TRACK CAPITAL, LP holds the second largest percentage of outstanding shares, with 8.2014% or 3.49 million shares worth $70.65 million as of 2024-06-30.
